484 related articles for article (PubMed ID: 20231398)
41. Isolation-drug resistance profile and molecular characterization of indigenous typical and atypical mycobacteria.
Khanum T; Rasool SA; Ajaz M; Khan AI
Pak J Pharm Sci; 2011 Oct; 24(4):527-32. PubMed ID: 21959816
[TBL] [Abstract][Full Text] [Related]
42. In vitro susceptibility of Mycobacterium kansasii to the difluorinated quinolone sparfloxacin using a broth microdilution and macrodilution MIC system.
Royo P; Martín-Casabona N; Martínez E; Andonegui M
Int J Tuberc Lung Dis; 1999 Apr; 3(4):349-53. PubMed ID: 10206507
[TBL] [Abstract][Full Text] [Related]
43. [In-vitro activity of two hybrid synthetic peptides having antimicrobial activity against mycobacteria].
Zerbini E; Andreu D; Tonarelli G; Sequeira MD
Rev Argent Microbiol; 2006; 38(4):221-3. PubMed ID: 17370578
[TBL] [Abstract][Full Text] [Related]
44. Use of the BACTEC system for drug susceptibility testing of Mycobacterium tuberculosis, M. kansasii, and M. avium complex.
Steadham JE; Stall SK; Simmank JL
Diagn Microbiol Infect Dis; 1985 Jan; 3(1):33-40. PubMed ID: 3917885
[TBL] [Abstract][Full Text] [Related]
45. N-benzylsalicylthioamides: highly active potential antituberculotics.
Dolezal R; Waisser K; Petrlíková E; Kunes J; Kubicová L; Machácek M; Kaustová J; Dahse HM
Arch Pharm (Weinheim); 2009 Feb; 342(2):113-9. PubMed ID: 19137534
[TBL] [Abstract][Full Text] [Related]
46. Discovery of novel 5-(ethyl or hydroxymethyl) analogs of 2'-'up' fluoro (or hydroxyl) pyrimidine nucleosides as a new class of Mycobacterium tuberculosis, Mycobacterium bovis and Mycobacterium avium inhibitors.
Shakya N; Srivastav NC; Bhavanam S; Tse C; Desroches N; Agrawal B; Kunimoto DY; Kumar R
Bioorg Med Chem; 2012 Jul; 20(13):4088-97. PubMed ID: 22664188
[TBL] [Abstract][Full Text] [Related]
47. [Comparison of in vitro antimicrobial activities of ofloxacin, levofloxacin, ciprofloxacin, and sparfloxacin against various mycobacteria].
Kawahara S; Tada A; Nagare H
Kekkaku; 2001 Apr; 76(4):357-62. PubMed ID: 11398326
[TBL] [Abstract][Full Text] [Related]
48. [In vitro activities of rifabutine and rifampicin against various mycobacteria, especially Mycobacterium tuberculosis and Mycobacterium avium complex].
Saito H; Sato K; Tomioka H
Kekkaku; 1988 Mar; 63(3):167-72. PubMed ID: 2836649
[No Abstract] [Full Text] [Related]
49. [Effect of some biocides on non-tuberculous mycobacteria].
León CI; Pardo YP; Ramírez CX
Biomedica; 2002 Jun; 22(2):133-40. PubMed ID: 12152479
[TBL] [Abstract][Full Text] [Related]
50. [In vitro susceptibilities of Mycobacterium avium and Mycobacterium intracellulare to new macrolides, new quinolones, and antituberculous drugs on Dubos agar medium].
Ogawa K; Miwa T; Sasamoto M; Sasaki T; Tsuda M; Honda K; Furui H; Torii K; Takagi K
Kekkaku; 1992 Nov; 67(11):735-8. PubMed ID: 1487866
[TBL] [Abstract][Full Text] [Related]
51. In Vitro Activity of 3-Triazeneindoles against Mycobacterium tuberculosis and Mycobacterium avium.
Nikonenko BV; Kornienko A; Majorov K; Ivanov P; Kondratieva T; Korotetskaya M; Apt AS; Salina E; Velezheva V
Antimicrob Agents Chemother; 2016 Oct; 60(10):6422-4. PubMed ID: 27503657
[TBL] [Abstract][Full Text] [Related]
52. Rapid mycobacteria drug susceptibility testing using Gel Microdrop (GMD) Growth Assay and flow cytometry.
Akselband Y; Cabral C; Shapiro DS; McGrath P
J Microbiol Methods; 2005 Aug; 62(2):181-97. PubMed ID: 16009276
[TBL] [Abstract][Full Text] [Related]
53. Synthesis and evaluation of rifabutin analogs against Mycobacterium avium and H(37)Rv, MDR and NRP Mycobacterium tuberculosis.
Figueiredo R; Moiteiro C; Medeiros MA; da Silva PA; Ramos D; Spies F; Ribeiro MO; Lourenço MC; Júnior IN; Gaspar MM; Cruz ME; Curto MJ; Franzblau SG; Orozco H; Aguilar D; Hernandez-Pando R; Costa MC
Bioorg Med Chem; 2009 Jan; 17(2):503-11. PubMed ID: 19119013
[TBL] [Abstract][Full Text] [Related]
54. Comparison of the activities of the lantibiotics nisin and lacticin 3147 against clinically significant mycobacteria.
Carroll J; Draper LA; O'Connor PM; Coffey A; Hill C; Ross RP; Cotter PD; O'Mahony J
Int J Antimicrob Agents; 2010 Aug; 36(2):132-6. PubMed ID: 20547041
[TBL] [Abstract][Full Text] [Related]
55.
Pang Y; Zheng H; Tan Y; Song Y; Zhao Y
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242674
[TBL] [Abstract][Full Text] [Related]
56. Antitubercular agents. Part 1: synthesis of phthalimido- and naphthalimido-linked phenazines as new prototype antitubercular agents.
Kamal A; Hari Babu A; Venkata Ramana A; Sinha R; Yadav JS; Arora SK
Bioorg Med Chem Lett; 2005 Apr; 15(7):1923-6. PubMed ID: 15780634
[TBL] [Abstract][Full Text] [Related]
57. Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
Tomioka H; Sato K; Kajitani H; Akaki T; Shishido S
Antimicrob Agents Chemother; 2000 Feb; 44(2):283-6. PubMed ID: 10639351
[TBL] [Abstract][Full Text] [Related]
58. In vitro efficacy of Linezolid on clinical strains of Mycobacterium tuberculosis and other mycobacteria.
Molicotti P; Ortu S; Bua A; Cannas S; Sechi LA; Zanetti S
New Microbiol; 2006 Oct; 29(4):275-80. PubMed ID: 17201094
[TBL] [Abstract][Full Text] [Related]
59. Synergistic antimycobacterial activity between ethambutol and the beta-lactam drug cefepime.
Abate G; Hoffner SE
Diagn Microbiol Infect Dis; 1997 Jul; 28(3):119-22. PubMed ID: 9294701
[TBL] [Abstract][Full Text] [Related]
60. Activity of ciprofloxacin and other fluorinated quinolones against mycobacteria.
Young LS; Berlin OG; Inderlied CB
Am J Med; 1987 Apr; 82(4A):23-6. PubMed ID: 3107379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
